Premium
Effects of amiloride on plasma and total body potassium, blood pressure, and the renin‐angiotensin‐aldosterone system in thiazide‐treated hypertensive patients
Author(s) -
Svendsen Ulrik Gerner,
Ibsen Hans,
Rasmussen Sten,
Leth Arne,
Nielsen Meta Damkjær,
DigePetersen Harriet,
Giese Jørn
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.196
Subject(s) - hydrochlorothiazide , aldosterone , plasma renin activity , medicine , endocrinology , renin–angiotensin system , blood pressure , amiloride , thiazide , chemistry , potassium , angiotensin ii , essential hypertension , sodium , organic chemistry
Total body potassium content, plasma potassium concentration, blood pressure, and plasma concentrations of renin, angiotensin II, and aldosterone were measured in patients with essential hypertension after a run‐in period of 8 wk on a regimen of hydrochlorothiazide (median dosage 75 mg/day). Patients were then randomly assigned to continued hydrochlorothiazide therapy (group I) or to receive adjunctive treatment with amiloride (group II, median dosage 15 mg/day or 5 mg per 25 mg hydrochlorothiazide) for the following 3 mo. There were no changes in group I patients during 3 mo on hydrochlorothiazide in plasma potassium, total body potassium content, or the renin‐angiotensin‐aldosterone system. Blood pressure was also unchanged. In group II patients addition of amiloride to hydrochlorothiazide induced a rise in plasma and total body potassium of approximately 15% and 4%. The potassium‐retaining effect was maintained throughout the 12‐wk period, although the maximal changes were observed after 8 wk of treatment. Supine blood pressure did not change, but there was a significant decrease in standing systolic blood pressure. There was a marked rise in plasma concentrations of renin, angiotensin II, and aldosterone. Clinical Pharmacology and Therapeutics (1983) 34, 448–453; doi: 10.1038/clpt.1983.196